Myristic acid C14:0; Myristoleic acid C14:1; Pentadecanoic acid C15:0; Palmitic acid C16:0; Palmitoleic acid C16:1; Stearic acid C18:0; Oleic acid C18:1; Linoleic acid C18:2n6; Alpha-Linolenic acid C18:3n3; Gamma-Linolenic acid C18:3n6; Arachidic acid C20:0; Eicosenoic acid C20:1; Eicosadienoic acid C20:2n6; Eicosatrienoic acid C20:3n3; Dihomo-Gamma-Linolenic acid; Arachidonic Acid (C20:4N6); Eicosapentaenoic Acid C20:5n-3; Behenic acid C22:0; Docosadienoic acid C22:2n6; Adrenic acid C22:4n6; Docosapentaenoic Acid C22:5n-3; Docosapentaenoic acid n6 C22:6; Docasahexaenoic Acid C22:6n-3; Lignoceric acid C24:0; Nervonic acid C24:1; Total Omega-3 Fatty Acids; Total Omega-6 Fatty Acids; EPA + DHA (20:5n3+22:6n3); OM3/OM6 Ratio; OM6/OM3 Ratio; AA/EPA Ratio
Back to Test Catalogue
Total Fatty Acids Profile, Blood
Test ID: TFAP B
Orderable by Ontario ND
Test
Method
GC-FID
Report Includes
Specimens
Whole Blood
Test Location
University Health Network, 200 Elizabeth St, 11E-444, Toronto ON M5G 2C4
Test Version
20-Apr-2023
Specimen
Specimens
Whole Blood
Collection Containers
Preferred
Lavender top EDTA whole blood
Sample Volume
5 mL
Minimum Volume
1 mL
Collection & Handling
Handling Information
Store and send cold.
Stability
| Refrigerated | 2 months |
|---|
Rejection Criteria
| Specimen | Serum |
|---|
Test Version
20-Apr-2023
Performance / Interpretation
Method
GC-FID
Turnaround Time
10 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| (All reported fatty acids) | % weight |
|
||
| Docasahexaenoic Acid C22:6n-3 | % weight |
|
||
|
DHA (Docosahexaenoic Acid) scores of >4.50 are associated with low risk of CHD.
|
||||
| Total Omega-3 Fatty Acids | % weight |
|
||
|
Total Omega-3 scores of > 7.20 are associated with low risk of CHD
|
||||
| Total Omega-6 Fatty Acids | % weight |
|
||
|
Interpretive guidelines for Omega-6 scores have not been established.
|
||||
| EPA + DHA (20:5n3+22:6n3) | % weight |
|
||
|
EPA (Eicosapentaenoic Acid) plus DHA scores of > 4.60 are associated with low risk of fatal heart disease.
|
||||
| OM3/OM6 Ratio |
|
|||
|
An Omega-3/Omega-6 score of 1:3 is consistent with anti-inflammation.
|
||||
| AA/EPA Ratio |
|
|||
|
Interpretive guidelines for the ratio of AA (Arachidonic Acid) to EPA have not been established.
|
||||
Test Location
University Health Network, 200 Elizabeth St, 11E-444, Toronto ON M5G 2C4
Test Version
20-Apr-2023
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| TFAP B | 63261Myristic acid C14:0 | |
| 63262Myristoleic acid C14:1 | ||
| 63263Pentadecanoic acid C15:0 | ||
| 63264Palmitic acid C16:0 | ||
| 63265Palmitoleic acid C16:1 | ||
| 63266Stearic acid C18:0 | ||
| 63267Oleic acid C18:1 | ||
| 63268Linoleic acid C18:2n6 | % Weight | |
| 63269Alpha-Linolenic acid C18:3n3 | % Weight | |
| 63270Gamma-Linolenic acid C18:3n6 | % Weight | |
| 63271Arachidic acid C20:0 | % Weight | |
| 63272Eicosenoic acid C20:1 | % Weight | |
| 63273Eicosadienoic acid C20:2n6 | % Weight | |
| 63274Eicosatrienoic acid C20:3n3 | % Weight | |
| 63275Dihomo-Gamma-Linolenic acid | % Weight | |
| 63276Arachidonic Acid (C20:4N6) | % Weight | |
| 63277Eicosapentaenoic Acid C20:5n-3 | % Weight | |
| 63278Behenic acid C22:0 | % Weight | |
| 63279Docosadienoic acid C22:2n6 | % Weight | |
| 63280Adrenic acid C22:4n6 | % Weight | |
| 63281Docosapentaenoic Acid C22:5n-3 | % Weight | |
| 63282Docosapentaenoic acid n6 C22:6 | % Weight | |
| 63283Docasahexaenoic Acid C22:6n-3 | % Weight | |
| 63284Lignoceric acid C24:0 | % Weight | |
| 63285Nervonic acid C24:1 | % Weight | |
| 63286Total Omega-3 Fatty Acids | % Weight | |
| 63287Total Omega-6 Fatty Acids | % Weight | |
| 63288EPA + DHA (20:5n3+22:6n3) | % Weight | |
| 63289OM3/OM6 Ratio | ||
| 63290OM6/OM3 Ratio | ||
| 63291AA/EPA Ratio |
Test Version
20-Apr-2023